1,721,201 research outputs found
Trapianto di isole e sostituzione della funzione beta cellulare per la terapia del diabete
No full textFelix dies natalis, insulin... ceterum autem censeo "beta is better"
No full textOne hundred years after its discovery, insulin remains the life-saving therapy for many patients with diabetes. It has been a 100-years-old success story thanks to the fact that insulin therapy has continuously integrated the knowledge developed over a century. In 1982, insulin becomes the first therapeutic protein to be produced using recombinant DNA technology. The first "mini" insulin pump and the first insulin pen become available in 1983 and 1985, respectively. In 1996, the first generation of insulin analogues were produced. In 1999, the first continuous glucose-monitoring device for reading interstitial glucose was approved by the FDA. In 2010s, the ultra-long action insulins were introduced. An equally exciting story developed in parallel. In 1966. Kelly et al. performed the first clinical pancreas transplant at the University of Minnesota, and now it is a well-established clinical option. First successful islet transplantations in humans were obtained in the late 1980s and 1990s. Their ability to consistently re-establish the endogenous insulin secretion was obtained in 2000s. More recently, the possibility to generate large numbers of functional human β cells from pluripotent stem cells was demonstrated, and the first clinical trial using stem cell-derived insulin producing cell was started in 2014. This year, the discovery of this life-saving hormone turns 100 years. This provides a unique opportunity not only to celebrate this extraordinary success story, but also to reflect on the limits of insulin therapy and renew the commitment of the scientific community to an insulin free world for our patients
SULFONAMIDES USEFUL IN THE PREVENTION OF DIABETES
No full textThe use of sulfonamides of formula (I) wherein R and R1 are as defined in the description, for the preparation of medicaments for the prevention of diabetes, in particular of type-1 diabetes is herein disclose
Cell therapy for type 1 diabetes: from islet transplantation to stem cells
No full textThe field of cell therapy of type 1 diabetes is a particularly interesting example in the scenario of regenerative medicine. In fact, β cell replacement has its roots in the experience of islet transplantation, which began 40 years ago, and is currently a rapidly accelerating field, with several ongoing clinical trials using β cells derived from stem cells
Monitoring Inflammation, Humoral and Cell-mediated Immunity in Pancreas and Islet Transplants
No full textThe contribution of hematopoietic stem cells to beta-cell replacement
No full textHemopoietic stem cells (HSCs) are commonly used for curing malignant and nonmalignant hematopoiesis disorders. In recent years, HSC potential giving rise to multilineage progeny has been reported. This issue, together with their availability and number, has made them ideal candidates for beta-cell replacement in diabetic patients. HSC capacity to differentiate to insulin-producing cells has been at the center of debate for the past 5 years and it now seems that their role could more likely be that of helper cells able to facilitate survival or stimulate proliferation of endogenous beta cells. In addition, clinical studies are ongoing about the possible use of HSCs to stop autoimmune destruction at the onset of diabetes or to induce tolerance through microchimerism in pancreatic islet transplantation
- …
